ClinicalTrials.gg
CompletedNCT04236960Updated Jan 22, 2020

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

A Phase 1 interventional study of Meningococcal Group ACYW135 Conjugate Vaccine in Meningococcal Infections, sponsored by Walvax Biotechnology Co., Ltd.. Completed at 1 site in China. Open to participants aged 2 Months to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by Walvax Biotechnology Co., Ltd. · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Months to 55 Years
Sex
All
01

Study summary

A single-center and open-labeled Phase I study, designed to evaluate the safety by observing the occurrence of adverse events and change of hematology, liver and renal function after vaccination of a meningococcal group A, C, Y, and W135 conjugate vaccine in healthy population aged 2 months to 55 years old.

02

Conditions studied

  • Meningococcal Infections

Keywords

  • Meningitis, Meningococcal, Serogroup A
  • Meningitis, Meningococcal, Serogroup C
  • Meningitis, Meningococcal, Serogroup Y
  • Meningitis, Meningococcal, Serogroup W135
03

In context

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

This study's enrollment of 100 is below the median of 456 across 214 interventional studies indexed under Meningococcal Infections.

Browse Meningococcal Infections studies →

Lead sponsor

Walvax Biotechnology Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy children, adolescents and adults (age range: 2 months to 55 years old) based on medical history, physical examination or judgement of the investigator
  • Subjects aged ≥18 years old voluntarily agree to participate in this clinical study and sign the form; or for subjects aged \<18 years old, the legal guardian voluntarily agrees that his/her child to participate in this clinical study, and sign the informed consent form. For juveniles aged ≥8 years old, both the subject and his/her legal guardians should voluntarily agree to participate in this clinical study and sign the informed consent form.
  • The subject and his/her legal guardians as well as the family members are able to follow the request of clinical study protocol.
  • Subjects aged 2 or 3 months should have no vaccination history of any meningococcal vaccine; subjects aged 7\~23 months should have not received any other meningococcal vaccine except the meningococcal group A polysaccharide vaccine included in National Immunization Program, and the time since last vaccination of meningococcal group A polysaccharide vaccine should be >6 months; for subjects ≥2 years, the time since last vaccination of meningococcal vaccine should be >2 years.
  • For subjects aged ≥2 years, there should be no abnormal hematology, liver and renal function results judged by the investigator before immunization.
  • Subjects should not receive any attenuated 14 days, or inactivated vaccine 7 days before or after vaccination.
  • Axillary temperature ≤37.0℃.

Exclusion Criteria for First Dose:

  • Subjects aged 2 or 3 months at enrollment with birth weight \<2.5 kg.
  • Subjects aged 2 or 3 months at enrollment had received blood products and immunoglobin after birth; subjects of other age groups had received blood products or immunoglobin in \<3 months before vaccination.
  • Subjects aged \<12 months at enrollment are diagnosed as with pathological jaundice or have a history of pathological jaundice.
  • Subjects aged \<2 months at enrollment had abnormal labor (dystocia, assisted instrumental delivery) or with the history of asphyxia or nervous damage.
  • Subjects aged ≥18 years who are planning pregnancy, or are pregnant, or are breastfeeding.
  • Subjects aged ≥18 years with uncontrollable hypertension (during screening: systolic BP >140 mmHg or diastolic BP >90 mmHg).
  • Subjects are known to be allergic to certain components contained in the vaccine (mainly include: capsular polysaccharide of meningococcal group A, group C, group Y, or group W135, diphtheria toxoid or diphtheria antigen).
  • Subjects with the history of serious allergy to any vaccine or drug. (including but not limited to: allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction [Arthus reaction]).
  • Subjects with the history of meningitis.
  • Subjects with moderate to severe fever (axillary temperature ≥38.0℃) in last 3 days.
  • Subjects with the history or family history of convulsion, seizure, encephalopathy, or psychiatric disorders.
  • Subjects with definite diagnosis of thrombocytopenia or other coagulation disorders.
  • Subjects with primary or secondary immunological dysfunction, including infection, disorder or resection of thyroid, pancreas, liver, spleen or kidney; or needed treatment due to thyroid disorders in last 12 months (time interval \<12 months).
  • Subjects have received therapy, cytotoxic therapy, hormone (not include corticosteroid hormone spray for allergic rhinitis, epithelial corticosteroid hormone for acute and non-complicated dermatitis) in last 6 months (time interval \<6 months).
  • Subjects with known congenital malformation, developmental disabilities or clinically confirmed serious chronic diseases (e.g., Down syndrome, diabetes mellitus, sickle cell anemia or nervous disease, Guillain-Barre syndrome, etc.).
  • Subjects with known or suspected diseases that are likely to affect the vaccination by investigators' judgement, such as: serious respiratory diseases, acute infection or the active period of chronic disease, serious cardiovascular diseases, liver and renal diseases, malignant tumors, serious infectious or allergic skin diseases.
  • Subjects are participating or plan to participate in other clinical trials of investigational medications.
  • Any other conditions that may influence the evaluation of clinical study by investigators' judgement.

Exclusion Criteria for Second and Third Dose:

  • New conditions that conforms with the exclusion criteria for first dose.
  • Subjects that develop grade 4 adverse reactions after vaccination of investigational vaccine.
  • Subjects that develop serious allergic reactions after vaccination of investigational vaccine.
  • Any other conditions that may influence the evaluation of clinical study by investigators' judgement based on the exclusion criteria for first dose.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    18~55 yrs

    1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.

    Biological: Meningococcal Group ACYW135 Conjugate Vaccine

  • Experimental
    2~17 yrs

    1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.

    Biological: Meningococcal Group ACYW135 Conjugate Vaccine

  • Experimental
    7~23 mos

    2 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between the first and second dose.

    Biological: Meningococcal Group ACYW135 Conjugate Vaccine

  • Experimental
    3 mos

    3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between every two doses.

    Biological: Meningococcal Group ACYW135 Conjugate Vaccine

  • Experimental
    2 mos

    3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. Two-month interval between every two doses.

    Biological: Meningococcal Group ACYW135 Conjugate Vaccine

Interventions

  • BiologicalMeningococcal Group ACYW135 Conjugate Vaccine

    1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events after each vaccination

    Percentage of subjects with local and systemic adverse events after each dose of vaccination

    Time frame: 30 days after vaccination

Secondary outcomes

  1. Incidence of serious adverse events after vaccination

    Percentage of subjects with serious adverse events from day 0 to 6 months after last dose

    Time frame: day 0 to 6 months after last dose

  2. Blood routine in 2 years and above subjects

    content of hemoglobin(g/dL)、white blood cell count(WBC)、blood platelet count(PLT)3 days after vaccination in 2 years and above subjects

    Time frame: 3 days after vaccination

  3. Liver function in 2 years and above subjects

    Alanine aminotransferase(ALT),Aspartate aminotransferase(AST),Total bilirubin(TBIL) 3 days after vaccination in 2 years and above subjects

    Time frame: 3 days after vaccination

  4. Renal function in 2 years and above subjects

    Creatinine(CR),Urea nitrogen(BUN)3 days after vaccination in 2 years and above subjects

    Time frame: 3 days after vaccination

07

Study locations

1 site
  • Guangdong Provincial Center for Disease Control and Prevention
    Guangzhou, Guangdong, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2019, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2018
First posted
Jan 22, 2020
StartActual
Jul 17, 2018
Primary completionActual
Sep 16, 2019
CompletionActual
Nov 28, 2019
Last update
Jan 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04236960
Lead sponsor
Walvax Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 22, 2020
Start date
Jul 17, 2018
Primary completion
Sep 16, 2019
Completion
Nov 28, 2019
Last update
Jan 22, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion